Bottom Line Up Front: VA rates eczema (all subtypes — atopic dermatitis, contact dermatitis, dyshidrotic eczema) under Diagnostic Code 7806 at four levels: 0%, 10%, 30%, or 60%. There is no 100% schedular rating for eczema. But here is the part most veterans miss: you do not need widespread skin coverage to reach the maximum 60% rating. If you have been on constant or near-constant systemic therapy — oral corticosteroids, biologic injections like dupilumab (Dupixent), or oral JAK inhibitors like upadacitinib (Rinvoq) — for the past 12 months, you qualify for 60% regardless of how your skin looks on exam day. This guide breaks down both rating pathways, the topical vs. systemic distinction that decides everything, secondary conditions that stack on top of 60%, and how to prepare for a C&P exam that captures the full picture.

In This Article

DC 7806: The Rating Code for Eczema

Every form of eczema and dermatitis — atopic dermatitis, contact dermatitis, dyshidrotic eczema, nummular eczema, seborrheic dermatitis — is rated under the same diagnostic code: DC 7806, found at 38 CFR § 4.118. This code uses the General Rating Formula for the Skin, which evaluates two things independently:

  1. Body surface area (BSA) — the percentage of your total body or exposed areas covered by active lesions
  2. Treatment intensity — the type and duration of therapy required over the past 12 months

The VA rates you on whichever pathway produces the higher rating. This is critical. A veteran whose skin looks clear on exam day but who has been on oral prednisone for 11 months qualifies for 60% under the treatment pathway alone. The skin does not need to be actively flaring at the time of the examination.

Key Regulatory Language: The Federal Register commentary on the 2018 final rule (83 FR 32592) states explicitly: “If constant or near-constant systemic therapy [is required], regardless of the extent of skin involvement at the time of examination, the veteran would be entitled to the highest evaluation.”

The Four Rating Levels (0% to 60%)

Rating Body Surface Area Criteria Treatment Criteria
0% Less than 5% of entire body, or less than 5% of exposed areas No more than topical therapy required during the past 12 months
10% At least 5% but less than 20% of entire body, or at least 5% but less than 20% of exposed areas Intermittent systemic therapy such as corticosteroids or immunosuppressive drugs required for a total duration of less than 6 weeks during the past 12 months
30% 20% to 40% of entire body, or 20% to 40% of exposed areas Systemic therapy such as corticosteroids or immunosuppressive drugs required for a total duration of 6 weeks or more (but not constantly) during the past 12 months; or constant or near-constant topical corticosteroid therapy during the past 12 months
60% More than 40% of entire body, or more than 40% of exposed areas Constant or near-constant systemic therapy such as corticosteroids, immunosuppressive drugs, or other immunosuppressive therapies required during the past 12 months

Notice the jump between 30% and 60%. The dividing line is one word: systemic. Constant or near-constant topical therapy caps you at 30%. Constant or near-constant systemic therapy gets you to 60%. That single distinction is where most eczema claims are won or lost.

Body Surface Area: How Percentages Are Calculated

The VA uses two body surface area measurements, and you qualify for your rating if either one meets the threshold:

The exposed-area pathway is the easier one to meet. If eczema affects your face and both hands, you may already be above the 20% exposed-area threshold for a 30% rating — even though those same areas represent a small fraction of your total body.

Calculating Your Own Percentage

The formula is straightforward:

(Affected area in square inches) ÷ (denominator) × 100 = percentage

For exposed areas, the denominator is 368 in². For total body, it is 2,636 in². If your eczema covers both hands (approximately 80 in² combined) and your face (approximately 60 in²), that is 140 ÷ 368 = 38% of exposed areas — which meets the 30% rating threshold.

C&P Examiner Problem: Examiners assess body surface area visually at the time of the exam, with no calibration standard. The DBQ form (VA Form 21-0960F-2, Section 5A) asks for “approximate” percentages. If your eczema flares and remits, the exam-day snapshot may dramatically underrepresent your typical coverage. Photograph your skin during active flares before your exam, and bring those photographs. Better yet, have your treating dermatologist document the BSA during an active flare in your medical records.

The Systemic vs. Topical Distinction

After the Federal Circuit’s 2017 decision in Johnson v. Shulkin (862 F.3d 1351), VA codified a bright-line definition in the 2018 final rule at 38 CFR § 4.118(a):

“Systemic therapy is treatment that is administered through any route (orally, injection, suppository, intranasally) other than the skin.”

In plain English:

This distinction matters enormously. A veteran applying triamcinolone cream to their arms every day is on constant topical therapy — maximum 30%. A veteran taking prednisone tablets every day for the same eczema is on constant systemic therapy — 60%.

What Counts as Systemic Therapy for Eczema

What Does NOT Count as Systemic Therapy

The Route Matters, Not the Drug Class: Ruxolitinib (Opzelura) is a JAK inhibitor applied as a cream — topical. Upadacitinib (Rinvoq) is a JAK inhibitor taken as a pill — systemic. Same drug class, different route, completely different rating outcome. Always check the route of administration.

The Corticosteroid Shortcut to 60%

The fastest path to a 60% eczema rating is the systemic therapy pathway. Here is how it works in practice:

If your dermatologist has prescribed oral corticosteroids (such as prednisone) on a constant or near-constant basis during the past 12 months, that alone qualifies you for the 60% rating under DC 7806. The regulation says “constant or near-constant systemic therapy such as corticosteroids” — it does not require the corticosteroids to be working, it does not require your skin to be clear, and it does not require a specific dosage.

What “Constant or Near-Constant” Means

VA does not define an exact number of weeks. The regulation distinguishes three tiers:

  1. Intermittent systemic therapy for less than 6 weeks — 10%
  2. Systemic therapy for 6 weeks or more but not constantly — 30%
  3. Constant or near-constant systemic therapy — 60%

In practice, BVA decisions treat systemic therapy prescribed and taken for most of the year — roughly 9 or more months out of 12 — as meeting the “constant or near-constant” threshold. Pharmacy fill records from the VA or your civilian pharmacy are the strongest evidence. If your prescription history shows monthly refills of an oral corticosteroid or biologic for 10 consecutive months, the treatment pathway is straightforward.

The 12-Month Clock: The relevant period runs backward from the date of the C&P examination or rating decision, not from the date you filed the claim. Make sure your medical records cover the 12 months immediately before your exam.

JAK Inhibitors and Biologics: The Underrecognized 60% Pathway

Since January 2022, the FDA has approved two oral JAK inhibitors specifically for moderate-to-severe atopic dermatitis: upadacitinib (Rinvoq) and abrocitinib (Cibinqo). Baricitinib (Olumiant) is also used for atopic dermatitis. All three are taken as daily pills.

Under VA’s own definition, oral JAK inhibitors are unambiguously systemic therapy. They are taken by mouth, not applied to the skin. A veteran taking upadacitinib daily for eczema is receiving continuous systemic therapy. If taken for most of a 12-month period, this directly qualifies for the 60% rating.

Similarly, biologic injections like dupilumab (Dupixent) — a subcutaneous injection given every two weeks — qualify as systemic therapy. BVA Decision 21068458 (2021) explicitly confirmed that biologic injections for atopic dermatitis warrant the 60% rating. Dupilumab is on the VA formulary, meaning veterans receiving it through VA already have clear documentation in their medical records.

Underrecognized Opportunity: Most VA eczema guides focus on corticosteroids when discussing the 60% systemic therapy pathway. But if you are taking a daily oral JAK inhibitor or receiving biologic injections every two weeks, you are already on constant systemic therapy. Your pharmacy records alone may be enough to establish the 60% rating.

The Topical-at-Scale Exception

The Federal Circuit in Johnson v. Shulkin acknowledged one important exception: topical corticosteroid treatment administered “on a large enough scale” could constitute systemic therapy. This is not a theoretical argument — multiple BVA decisions have applied it:

If your eczema requires topical corticosteroids applied to large portions of your body (covering your torso, extremities, and head simultaneously), this argument may convert your topical therapy into a systemic-equivalent for rating purposes. It is strongest when supported by medical records documenting the extent and frequency of application.

Important Limitation: The topical-at-scale argument applies most clearly to claims pending before August 13, 2018 (the effective date of the new bright-line definition). For newer claims, the regulatory definition is clear: systemic = not through the skin. The topical-at-scale argument is not guaranteed to succeed under the current rule, but it has been accepted in BVA decisions as recently as 2022.

Service Connection: Burn Pits, Chemicals, and Environmental Exposure

Before your eczema gets rated, you need service connection. There are several pathways:

Direct Service Connection

If your eczema started during or shortly after military service, direct service connection is the most straightforward path. You need:

Gulf War Presumptive (38 CFR § 3.317)

Gulf War veterans who served in the Southwest Asia theater of operations (from August 2, 1990 onward) and have a chronic, undiagnosed skin condition or medically unexplained chronic multi-symptom illness may qualify for presumptive service connection. This means no nexus letter is required. The condition must be rated at 10% or higher. The presumptive period extends through December 31, 2026.

Gulf War Veterans: If you served in Southwest Asia and have chronic eczema or dermatitis that the VA can rate at 10% or above, presumptive service connection under § 3.317 eliminates the need to prove a specific cause. File before the presumptive window closes at the end of 2026.

Burn Pit / Environmental Exposure

Veterans exposed to burn pits, jet fuel, solvents, depleted uranium, Agent Orange, or other environmental hazards during service have a strong basis for direct service connection for skin conditions that developed after deployment. A nexus letter from a dermatologist explaining the link between specific chemical or particulate exposures and the development of dermatitis is the key piece of evidence.

Secondary Service Connection (38 CFR § 3.310)

Eczema can be service-connected as secondary to another already service-connected condition. The most common pathway: PTSD causes eczema. The stress-immune pathway linking PTSD to eczema flares is well-documented in medical literature — chronically elevated cortisol and inflammatory cytokines drive skin inflammation. A nexus letter from a dermatologist or psychiatrist explaining this mechanism is persuasive.

Secondary Conditions That Stack on Top of Eczema

A 60% DC 7806 rating is the ceiling for eczema itself. But the combined rating can go much higher when you claim conditions caused or aggravated by your service-connected eczema. These are rated under separate diagnostic codes with no pyramiding issue because they measure different functional impairments.

Mental Health (Depression, Anxiety)

Chronic, visible, itching eczema causes documented rates of depression, anxiety, social isolation, and sleep disruption. These psychiatric conditions are rated under 38 CFR § 4.130 — a completely different rating formula from DC 7806. A veteran can hold a 60% DC 7806 skin rating and a separate 30%, 50%, or 70% mental health rating. No pyramiding bar applies because DC 7806 rates skin pathology while § 4.130 rates occupational and social impairment from psychiatric symptoms.

Sleep Disturbance

Nocturnal itching from eczema disrupts sleep. If no psychiatric rating already captures this, a veteran may have grounds for a separate sleep-related secondary claim. This is underutilized.

Scarring (DC 7800–7805)

When chronic eczema produces permanent scarring — particularly on the head, face, or neck — a separate rating under the scar codes may apply. DC 7800 rates disfigurement of the head, face, and neck up to 80%. The DBQ form (Section 2B) explicitly asks whether the skin condition causes scarring or disfigurement, triggering referral to the Scars/Disfigurement DBQ.

The Atopic Triad: Asthma and Allergic Rhinitis

The “atopic march” is a medically established progression: eczema in childhood or early adulthood leads to allergic rhinitis and asthma in approximately 30% of patients (NCBI StatPearls). Veterans with service-connected eczema who later develop asthma (DC 6602, rated up to 100%) or allergic rhinitis (DC 6522, rated at 10% without polyps or 30% with polyps) have a viable secondary service connection claim under 38 CFR § 3.310. This pathway requires a nexus letter from an allergist or dermatologist explaining the atopic march specific to the veteran’s medical history.

PACT Act Shortcut for Post-9/11 Veterans: If you are a post-9/11 veteran who deployed to a qualifying location and you have both eczema and asthma or chronic rhinitis, the PACT Act may provide a direct presumptive pathway for asthma and rhinitis — no nexus letter or atopic march argument needed. After October 31, 2023, there is no time limitation for filing. The atopic march secondary claim remains the primary pathway for pre-9/11 veterans.

Osteoarthritis

A peer-reviewed study published in Annals of the Rheumatic Diseases (Baker et al., 2023) found a 42–58% increased risk of osteoarthritis in patients with eczema or asthma, mediated through mast cell activation and allergic inflammation in joint tissue. Veterans with service-connected eczema who develop OA may have a secondary service connection pathway supported by this research. This requires a nexus letter citing the study and explaining the mechanism specific to the veteran.

C&P Exam Strategy

The C&P exam for eczema uses VA Form 21-0960F-2 (Skin Diseases DBQ). Here is what matters most and how to prepare:

Key DBQ Sections

Preparation Checklist

  1. Photograph your skin during active flares — date-stamped photos showing the extent of coverage. Bring printed copies to the exam.
  2. Bring your pharmacy records — a printed list of every eczema medication filled in the past 12 months, with dates and quantities. Highlight oral medications and injections.
  3. Ask your treating dermatologist to complete a private DBQ — especially Section 3A, where the doctor can explicitly note “oral JAK inhibitor (upadacitinib) taken daily — systemic therapy by route of administration.”
  4. Do not schedule your exam during a remission — if possible, request an exam during a flare. But remember: the treatment pathway does not depend on skin appearance at exam, so pharmacy records are your safety net.
  5. Document all affected body regions in writing — list every area where eczema appears (scalp, face, neck, hands, arms, torso, legs) so the examiner does not overlook areas that are between flares.
  6. Note secondary symptoms — sleep disruption, social avoidance, depression, anxiety, and scarring. These plant the seeds for secondary claims.
The Exam-Day Trap: Eczema flares and remits. If your skin is relatively clear on exam day, the BSA pathway may produce a low estimate. This is why the treatment-intensity pathway exists — your pharmacy records documenting 10 months of oral prednisone matter more than what the examiner sees on one afternoon. Make sure the examiner addresses Section 3A thoroughly.

The Clothing Allowance Nobody Tells You About

Under 38 CFR § 3.810, veterans who use medication prescribed for a service-connected skin condition that causes irreparable damage to outer garments qualify for an annual clothing allowance. In 2026, the rate is $1,053.19 per qualifying medication, with a maximum of four allowances per year.

If your eczema medications — topical corticosteroids, emollients, tar-based treatments — stain or damage your clothing, you may qualify. Two qualifying medications means $2,106.38 per year on top of your monthly disability compensation. Since December 2022, no annual reapplication is required once the benefit is established.

TDIU: When 60% Eczema Prevents You from Working

A veteran with a 60% DC 7806 eczema rating meets the schedular threshold for Total Disability Individual Unemployability (TDIU) under 38 CFR § 4.16(a). TDIU pays at the 100% rate ($3,938.58/month for a single veteran in 2026) even though the schedular combined rating is below 100%.

60% Is Necessary But Not Sufficient: Meeting the 60% threshold does not automatically grant TDIU. You must separately demonstrate that your eczema renders you unable to maintain substantially gainful employment. BVA Decision 22006558 (2022) confirmed this when it denied TDIU for a veteran with the maximum 60% DC 7806 rating because the veteran continued to work despite limitations. You need vocational evidence: physician statements about work limitations, employer documentation, and evidence of the treatment burden that interferes with holding a job.

For veterans whose eczema is rated below 60% but whose combined rating (with secondary conditions) reaches the schedular threshold, TDIU may also be available. And for those who cannot meet any schedular threshold, extraschedular TDIU under 38 CFR § 4.16(b) is a referral pathway that exists but requires VA to forward the case to the Director of Compensation Service.

Build Your Eczema Claim with VetAid

Upload your medical records and let our AI identify the strongest rating pathway, flag secondary conditions, and generate the documentation strategy that matches how VA actually rates DC 7806 claims.

Start Free Analysis

Frequently Asked Questions

What is the VA rating for eczema?

VA rates eczema under Diagnostic Code 7806 at four levels: 0%, 10%, 30%, or 60%. The rating is determined by two independent pathways — body surface area coverage and treatment intensity. You receive whichever pathway produces the higher rating. The maximum schedular rating under DC 7806 is 60%, but secondary conditions (depression, anxiety, scarring, asthma, allergic rhinitis) can push the combined rating significantly higher.

What percentage of body area qualifies for each rating?

Under DC 7806: less than 5% of the entire body or exposed areas = 0%. At least 5% but less than 20% = 10%. Between 20% and 40% = 30%. More than 40% = 60%. The VA measures both total body surface area (denominator: 2,636 in²) and exposed areas only (head, face, neck, and hands; denominator: 368 in²). You qualify based on whichever measurement is more favorable.

Does using steroid cream count for the 60% rating?

No — with one exception. Topical steroid creams (applied to the skin) are classified as topical therapy, which maxes out at 30% for constant or near-constant use. To reach 60%, you need systemic therapy: oral corticosteroid pills, biologic injections, oral JAK inhibitors, or other medications administered by a route other than the skin. The exception: BVA decisions have accepted that topical corticosteroids applied “on a large enough scale” (covering most of the body) can qualify as systemic therapy, particularly for claims pending before August 2018.

Can eczema be secondary to burn pit exposure?

Yes. Veterans who deployed to Iraq, Afghanistan, or other qualifying locations and developed eczema after exposure to burn pits, chemicals, or environmental hazards can file for service connection. Gulf War veterans with chronic dermatitis rated at 10% or higher may qualify for presumptive service connection under 38 CFR § 3.317 — no nexus letter required. This presumptive window extends through December 31, 2026. For all other veterans, a dermatologist’s nexus letter connecting the specific exposure to the development of eczema is the key evidence.

Legal References